Aptar Pharma highlights expanded services platform

  • Aptar Pharma

Aptar Pharma, a leading drug delivery systems provider, is pleased to be exhibiting at CPhI Worldwide 2019, the world’s largest pharmaceutical exhibition, which will take place November 5-7 in Frankfurt, Germany. More than 45,000 visitors and 2,500 international exhibitors are expected to attend this year’s three-day event.

At Stand 111D70, Aptar Pharma will be featuring its diverse portfolio of drug delivery systems, components and active packaging solutions, including their latest innovations addressing nasal, pulmonary, eye care, injectables and dermal drug delivery routes including:

  • PureHale – a revolutionary, portable and ready-to-use device designed to deliver natural care to upper airways
  • A dedicated Connectivity hub will host Aptar Pharma’s expanding range of connected drug delivery devices and show how Aptar is building a connected devices eco-system for digital medicines
  • Nanopharm’s SmartTrackTM - a novel approach to decrease program costs and avoid BE studies in OINDPs. SmartTrackTM will also be a featured stop on CPhI’s guided Innovation Tours on November 6 and 7, and has been entered in the 2019 CPhI Pharma Awards.

Aptar Pharma’s newly expanded Aptar Pharma Services platform will be introduced at this year’s CPhI. Offering early stage to commercialization services, Aptar Pharma has over 25 years’ experience supporting regulatory submissions. Leading experts from Aptar Pharma’s analytical services companies will be on hand to discuss how their value-added services can help customers accelerate and derisk their drug development journey:

  • Nanopharm, a leading provider of orally inhaled and nasal drug product design and development services.
  • Next Breath, a full-service cGMP lab specializing in analytical testing of drug delivery systems
  • Gateway Analytical, providing industry-leading particulate detection and predictive analytical services

Aptar CSP Technologies, part of the Aptar family, will be presenting their extensive portfolio of active packaging solutions including the award-winning XcelerateTM Development Services which can help expedite time-to-market for moisture- and oxygen-sensitive drugs.

Several of Aptar Pharma’s Injectables initiatives will also be featured. Aptar Pharma QuickStartTM – a sterile, ready-to-use early stage injectable development package now available for purchase on aptar.com/pharma. QuickStartTM is designed to accelerate and derisk time-to-market for start-ups, R&D, biotechs and university research organizations. Also, discover Aptar Pharma’s Injectable plans underway for expanding production capabilities and capacity worldwide.

On Wednesday, November 6, Aptar Pharma experts will present three back-to-back Pharma Insight Briefings, outlining the latest trends and technologies:

• “Driving Foreign Particulate Analysis: How to Choose Between Manual and Automated” (13:50-14:20). Presented by David Exline, President, Gateway Analytical, an Aptar Pharma company
• “Advantages of Nasal Powders for Drug Repurposing” (14:30–15:00). Presented by Dr Gerallt Williams, Director Scientific Affairs, Aptar Pharma
• “Beyond Pharmaceutical Packaging: New Solutions to Old Challenges” (15:10–15:40). Presented by Badre Hammond, Vice-President, Commercial Operations, Aptar CSP Technologies
These Pharma Insight Briefings are free-to-attend and will take place at location 110D50 in the InnoPack & P-MEC Theatre.

Aptar Pharma has been an exhibitor for many years at CPhI Worldwide, celebrating its 30th anniversary, bringing pharma professionals together to meet, discover and learn about the latest trends and ground-breaking ideas in the industry. Aptar Pharma welcomes the opportunity to once again demonstrate its wide-ranging expertise and latest drug delivery technologies, and meet with customers to see how Aptar can help meet their next drug delivery challenge.

Image: PureHale

See also

Aptar’s Nasal Unidose Device approved by US FDA

Aptar’s Nasal Unidose Device approved by US FDA

AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

Aptar Pharmas Freepod nasal spray device with GlaxoSmithKlines Otrivin wins prestigious WPO WorldStar 2019 award

Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

Aptar Pharma launches PureHale, a new portable and ready-to-use upper respiratory drug delivery solution

Aptar Pharma launches PureHale, a new portable and ready-to-use upper respiratory drug delivery solution

Aptar Pharma, a leading drug delivery systems provider, continues its commitment to meeting new market trends with the release of an industry first, PureHale, a new portable and ready-to-use drug delivery solution designed for upper respiratory care. PureHale is a revolutionary and intuitive device which – when used in combination with saline or other natural ingredient formulations – helps relieve the symptoms of upper respiratory system conditions.

Join Aptar Pharmas live webinar Good medicine: Solutions for sensitive injectable formulations

Join Aptar Pharma's live webinar "Good medicine: Solutions for sensitive injectable formulations"

Aptar Pharma, a leading provider of innovative drug delivery systems, will host a live educational webinar presenting the benefits of high quality film coated elastomeric components and the role they play in reducing patient and regulatory risk. Taking place on October 24, 2018, at 15.00 GMT, the webinar, entitled “Good Medicine: Solutions for Sensitive Injectable Formulations” will demonstrate how high quality film coated components meet compliance expectations while maintaining safety of supply for the drug product..

New technologies in ophthalmic drug delivery webinar hosted by Aptar Pharma

New technologies in ophthalmic drug delivery webinar hosted by Aptar Pharma

Aptar Pharma, a leading provider of innovative drug delivery systems, has announced it will be hosting a live, complimentary webinar titled “Optimizing Patient Adherence and Compliance in Eye Care” on November 21 at 11AM EST. The webinar will offer expert insight from Matthias Birkhoff, Vice President Business Development at Aptar Pharma, and Dr. Degenhard Marx, Director Scientific Affairs within the Aptar Pharma Consumer Health Care Division.

Aptar Pharmas electronic lockout device approved by EMA

Aptar Pharma's electronic lockout device approved by EMA

Aptar Pharma, a world leader in innovative drug delivery systems, is pleased to announce the approval by the European Medicines Agency (EMA) of the first integrated electronic nasal lockout device (e-Lockout) following a multi-year development with Takeda Pharmaceuticals International AG. Aptar Pharma agreed to supply Takeda with its e-Lockout device for a multidose nasal spray version of Instanyl®. The EMA has granted marketing authorization for this multidose nasal spray treatment under the name Instanyl DoseGuardTM.

Aptar Pharmas preservative free multi-dose ophthalmic squeeze dispenser launches in the U.S.

Aptar Pharma's preservative free multi-dose ophthalmic squeeze dispenser launches in the U.S.

Aptar Pharma, a global solution provider of innovative and proven aerosol, injection and spray delivery systems for biotech, healthcare and pharma products, has partnered with a leading eye care company to develop and launch a new eye drop product, which uses Aptar Pharma's innovative preservative free multi-dose Ophthalmic Squeeze Dispenser (OSD). This is the first preservative free multi-dose eye drop featuring Aptar Pharma's OSD in the United States.

  • Jo Webb
  • Product Info
  • English
  • Created 07 Oct 2019
  • Modified 07 Oct 2019
  • Hits 134